Interactive Features

FDA Alerts

FDA Accepts New Drug Application for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

07/23/2026

Stephanie Holland

The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...

The FDA accepted for review a...

07/23/2026

Oncology

Quiz

Neoadjuvant FOLFIRINOX for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma

11/25/2025

True or False: In the phase 3 PREOPANC-2 trial, neoadjuvant FOLFIRINOX significantly improved overall survival compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic...

True or False: In the phase 3...

11/25/2025

Oncology

Quiz

Impact of Tumor Treating Fields Plus Chemotherapy on Quality of Life for Patients With Pancreatic Cancer

10/07/2025

Do you know the primary finding regarding pain and quality of life outcomes from the PANOVA-3 trial evaluating the addition of tumor treating fields to gemcitabine/nab-paclitaxel? Take our quick quiz to find out!

Do you know the primary finding...

10/07/2025

Oncology

Quiz

Tocilizumab Plus Gemcitabine and Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer

09/23/2025

In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?

In the phase 2 PATCO trial...

09/23/2025

Oncology

Quiz

Quiz: Is FOLFIRINOX a Superior Treatment for Patients With Resectable Pancreatic Cancer?

09/08/2021

True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.

True or false: Results from the...

09/08/2021

Oncology

Quiz

Quiz: Is FOLFIRINOX a Superior Treatment for Patients With Resectable Pancreatic Cancer?

09/08/2021

True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.

True or false: Results from the...

09/08/2021

Oncology

Quiz

Quiz: Do Molecularly-Matched Therapies Improve OS for Pancreatic Cancer?

08/12/2021

Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.

Molecularly-matched treatments...

08/12/2021

Oncology

Quiz

Quiz: What is the Median Age of Patients Diagnosed with Pancreatic Cancer?

08/03/2021

True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.

True or False: The median age of...

08/03/2021

Oncology

Test Your Knowledge

Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?

08/06/2020

Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?

Which combination yielded...

08/06/2020

Oncology

Test Your Knowledge

Quiz: Adjuvant Chemoradiation for High-Risk Pancreatic Cancer

09/26/2019

True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.

True or False: Adding radiation...

09/26/2019

Oncology

Recent News

FDA Approval

FDA Approves and Launches Generic Lanreotide Injection Referencing Somatuline Depot

09/23/2026

Stephanie Holland

The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...

The FDA approved Amneal’s...

09/23/2026

Oncology

News

NHS-Galleri Trial Finds No Significant Reduction in Stage III or IV Cancer With Multicancer Blood Screening

09/23/2026

Stephanie Holland

Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...

Results from the randomized...

09/23/2026

Oncology

News

NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera

09/22/2026

Stephanie Holland

Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...

Updated NCCN Guidelines...

09/22/2026

Oncology

News

FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes

09/22/2026

Emily Estrada

The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...

The FDA granted Fast Track...

09/22/2026

Oncology

News

Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer

09/22/2026

Stephanie Holland

Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...

Results from the phase 3...

09/22/2026

Oncology

News

Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

09/21/2026

Emily Estrada

Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...

Results from the phase 3...

09/21/2026

Oncology

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology